Aflatoxin B1-2,3-oxide as a probable intermediate in the covalent binding of aflatoxins B1 and B2 to rat liver DNA and ribosomal RNA in vivo.
Administration of[3H]aflatoxin B2 (2,3-dihydroaflatoxin B1)(AFB2) to male rats resulted in levels of hepatic DNA- and ribosomal(r)RNA-aflatoxin adducts that were about 1% of those for rats given [3H]aflatoxin B1(AFB1). The levels of hepatic protein-aflatoxin adducts were 35 to 70% as great for AFB2-treated as compared to AFB1-treated rats...
D000348:Aflatoxins / Q000378:metabolism* / Q000633:toxicity; D000818:Animals; D002273:Carcinogens; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced; D004247:DNA / Q000378:metabolism*; D007421:Intestine, Small / Q000378:metabolism; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism*; D008113:Liver Neoplasms / Q000139:chemically induced; D008297:Male; D009374:Neoplasms, Experimental / Q000139:chemically induced; D010087:Oxides / Q000378:metabolism; D010634:Phenobarbital / Q000494:pharmacology; D010902:Pituitary Gland / Q000502:physiology; D011485:Protein Binding; D012335:RNA, Ribosomal / Q000378:metabolism*; D051381:Rats; D013154:Spleen / Q000378:metabolism
D000348:Aflatoxins; D002273:Carcinogens; D010087:Oxides; D012335:RNA, Ribosomal; D004247:DNA; D010634:Phenobarbital